Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials.
BACKGROUND
Acute liver failure (ALF) is a rare but highly mortal condition without liver transplantation (LT). N-acetylcysteine (NAC), a glutathione precursor that detoxifies the reactive metabolite of acetaminophen and replenishes hepatic glutathione stores, is a highly effective drug for the prevention of ALF caused by acetaminophen. However, therapeutic use of NAC in non-acetaminophen-induced ALF (NAI-ALF) including alcohol intoxication, hepatitis virus infection, or drug and toxin-related hepatotoxicity is still inconclusive. The aim of this article is using meta-analysis method to analyze recent prospective clinical trials for the safety and efficacy of NAC in patients with ALF not caused by acetaminophen poisoning.


METHODS
Prospective clinical trials comparing efficacy and safety between NAC and control in the treatment of NAI-ALF were identified by searching Pubmed (2000-2014) and EMBASE (2000-2014) using the search terms acetylcysteine or NAC and NAI-ALF. The primary outcome was overall survival. Secondary outcomes included liver transplantation-free survival, post transplantation survival, length of ICU and hospital stays, and the relationship with coma grade. The safety profiles were also analyzed.


RESULTS
Four clinical trials were selected for meta-analysis. A total of 331 patients receiving treatment with NAC (oral or intravenously) and 285 patients in control group were included for meta-analysis. No statistical difference was identified between NAC group and control group for overall survival [236/331 (71%) vs 191/285 (67%); 95% CI 1.16 (0.81-1.67); P=0.42]. However, there were significant differences between NAC group and control group regarding the survival with native liver [112/273 (41%) vs 68/226 (30%); 95% CI 1.61 (1.11-2.34); P=0.01] and post-transplantation survival [78/91 (85.7%) vs 50/70 (71.4%); 95% CI 2.44 (1.11-5.37); P=0.03]. The identified side effects of NAC included nausea, vomiting, and diarrhea or constipation. Rarely, it could cause rashes, fever, headache, drowsiness, low blood pressure, and elevated serum transaminase levels in a patient with cystic fibrosis. At the dose used for acetaminophen toxicity, acetylcysteine does not have hepatotoxic effects.


CONCLUSIONS
NAC is safe for NAI-ALF. It can prolong patients' survival with native liver without transplantation and survival after transplantation, but it cannot improve the overall survival.
Department of Gastroenterology, Jinan Military General Hospital, 25, Shifan Road, Jinan, Shandong, 250031, China.
Jinhua
J
Hu
The fifth People's Hospital of Jinan, Jinan, Shandong, 250031, China.
Qizhi
Q
Zhang
The fifth People's Hospital of Jinan, Jinan, Shandong, 250031, China.
Xingye
X
Ren
Department of Gastroenterology, Jinan Military General Hospital, 25, Shifan Road, Jinan, Shandong, 250031, China.
Ziqin
Z
Sun
Department of Gastroenterology, Jinan Military General Hospital, 25, Shifan Road, Jinan, Shandong, 250031, China. Electronic address: qizhenquan01@163.com.
Qizhen
Q
Quan
D000082:Acetaminophen / Q000009:adverse effects; D000111:Acetylcysteine / Q000008:administration & dosage*; D000284:Administration, Oral; D002986:Clinical Trials as Topic; D016166:Free Radical Scavengers / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D017114:Liver Failure, Acute / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D016896:Treatment Outcome
D016166:Free Radical Scavengers; D000082:Acetaminophen; D000111:Acetylcysteine